[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-565777-105":3,"detail-sidebar-cat-1-en-105":81,"doc-detail-565777-en":127},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","form-10-k-annual-report-pursuant-to-section-13-or-15d-merck-co-inc","FORM 10-K - Annual Report Pursuant to Section 13 or 15(d) - Merck & Co., Inc.","","Form 10-K filing by Merck & Co., Inc. submitted to the United States Securities and Exchange Commission for the fiscal year ended December 31, 2025. The cover information includes the filing type, commission file number, registrant details, registered securities, trading symbols, and exchange listings. It also provides eligibility and compliance checkmarks for SEC reporting obligations, internal control assessment, and auditor attestation, followed by key metrics such as shares outstanding and aggregate market value as of stated dates, plus referenced documents for Part III.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/template/","Template",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/template/general/","General",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/template/form-10-k-annual-report-pursuant-to-section-13-or-15d-merck-co-inc/565777/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/form-10-k-annual-report-pursuant-to-section-13-or-15d-merck-co-inc/565777.png","ImageObject",442,249,{"name":42,"@type":43},"pixelkiddo","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-10-13",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What filing form and reporting period does this document cover?","Question",{"text":63,"@type":64},"It is a Form 10-K annual report for the fiscal year ended December 31, 2025, submitted pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Who is the registrant and where is it located?",{"text":68,"@type":64},"The registrant is Merck & Co., Inc., with an address at 126 East Lincoln Avenue, Rahway, New Jersey 07065.",{"name":70,"@type":61,"acceptedAnswer":71},"What securities information is included on the cover?",{"text":72,"@type":64},"The cover lists securities registered pursuant to Section 12(b), including several notes due in different years, associated trading symbols, and the listed exchange as New York Stock Exchange.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},565777,1792164844,{"code":4,"msg":82,"data":83},"success",[84,89,94,99,104,109,114,119,124],{"id":85,"doc_module":22,"doc_module_name":25,"category_name":86,"show_sort_weight":87,"slug":88},11,"Presentations",90,"presentations",{"id":90,"doc_module":22,"doc_module_name":25,"category_name":91,"show_sort_weight":92,"slug":93},12,"Resumes",80,"resumes",{"id":95,"doc_module":22,"doc_module_name":25,"category_name":96,"show_sort_weight":97,"slug":98},14,"Invoices",70,"invoices",{"id":100,"doc_module":22,"doc_module_name":25,"category_name":101,"show_sort_weight":102,"slug":103},15,"Posters",60,"posters",{"id":105,"doc_module":22,"doc_module_name":25,"category_name":106,"show_sort_weight":107,"slug":108},16,"Social Media",50,"social-media",{"id":110,"doc_module":22,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},17,"Forms",40,"forms",{"id":115,"doc_module":22,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},18,"Letters",30,"letters",{"id":120,"doc_module":22,"doc_module_name":25,"category_name":121,"show_sort_weight":122,"slug":123},21,"Paper Templates",5,"papers-templates",{"id":125,"doc_module":22,"doc_module_name":25,"category_name":29,"show_sort_weight":4,"slug":126},158,"general-158",{"code":4,"msg":82,"data":128},{"doc_id":79,"user_id":129,"nickname":42,"user_avatar":130,"doc_module":22,"category_id":125,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":131,"file_id":132,"file_url":133,"file_type":134,"file_size":135,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":136,"language":137,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":138,"faqs":139,"seo_title":140,"seo_description":12,"update_tm":141,"read_time":142},962090883892,"https://ap-avatar.wpscdn.com/avatar/e00115db34f3e0f11b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1790152879550218658","UNITED STATES  \nSECURITIES AND EXCHANGE COMMISSION  \nWASHINGTON, D. C. 20549  \n_________________________________  \nFORM 10-K  \n☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934  \nFor the Fiscal Year Ended December 31, 2025  \nOR  \n☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934  \nFor the transition period from   to    \nCommission File No. 1-6571  \nMerck & Co., Inc.  \n126 East Lincoln Avenue  \nRahway New Jersey 07065  \n(908) 740-4000  \nNew Jersey 22-1918501  \n(State or other jurisdiction of incorporation) (I. R.S. Employer Identification No. )  \nSecurities Registered pursuant to Section 12(b) of the Act:  \nTitle of Each Class Common Stock ($0 .50 par value) 1.875% Notes due 2026 3.250% Notes due 2032 2.500% Notes due 2034 1.375% Notes due 2036 3.500% Notes due 2037  \n3.700% Notes due 2044  \n3.750% Notes due 2054  \nTrading Symbol(s) MRKMRK/26  \nMRK/32  \nMRK/34  \nMRK 36A  \nMRK/37  \nMRK/44  \nMRK/54  \nName of Each Exchange on which Registered New York Stock Exchange  \nNew York Stock Exchange  \nNew York Stock Exchange  \nNew York Stock Exchange  \nNew York Stock Exchange  \nNew York Stock Exchange  \nNew York Stock Exchange  \nNew York Stock Exchange  \nSecurities Registered pursuant to Section 12(g) of the Act: None  \nIndicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐  \nIndicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒  \nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) , and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐  \nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files) . Yes ☒ No ☐  \nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of“large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.  \nLarge accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐  \nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐  \nIndicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒  \nIf securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐  \nIndicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b) . ☐  \nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) . Yes ☐ No ☒  \nNumber of shares of Common Sto","cbCain7McoVbG9er","https://ap.wps.com/l/cbCain7McoVbG9er","pdf",2822431,266,"English","# Cover and Filing Type\n## Fiscal year and filing purpose\n# Registrant and Securities\n## Company address and incorporated jurisdiction\n## Securities registered under Section 12(b)\n## Securities registered under Section 12(g)\n# Eligibility and Compliance Checks\n## Well-known seasoned issuer status\n## Reporting requirements and electronic submission\n## Large accelerated filer and other company status\n# Key Financial and Corporate Metrics\n## Shares outstanding as of January 31, 2026\n## Aggregate market value as of June 30, 2025\n# Documents Incorporated by Reference\n## Proxy statement reference\n# Table of Contents\n## Part I items 1-4\n## Part II items 5-9C\n## Part III items 10-12","[{\"question\":\"What filing form and reporting period does this document cover?\",\"answer\":\"It is a Form 10-K annual report for the fiscal year ended December 31, 2025, submitted pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.\"},{\"question\":\"Who is the registrant and where is it located?\",\"answer\":\"The registrant is Merck \\u0026 Co., Inc., with an address at 126 East Lincoln Avenue, Rahway, New Jersey 07065.\"},{\"question\":\"What securities information is included on the cover?\",\"answer\":\"The cover lists securities registered pursuant to Section 12(b), including several notes due in different years, associated trading symbols, and the listed exchange as New York Stock Exchange.\"}]","FORM 10-K - Annual Report Pursuant to Section 13 or 15(d) - Merck & Co., Inc. | PDF",1791857978,93]